Drug Profile
Research programme: XTEN-based therapeutics - Amunix/Roche
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Amunix; Roche
- Class Peptides; Recombinant fusion proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Unspecified in USA
- 17 Jan 2022 Amunix has been acquired by Sanofi
- 27 Feb 2018 Preclinical trials in Undefined indication in USA (unspecified route) (Amunix pipeline, February 2018)